Cara Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
TVRD$1.41+47.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · December 31, 2024 · December 31, 2023 | ||||||
| Assets · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $37,903 | | $51,775 | ||
| Marketable securities | | — | | 48,983 | ||
| Accounts receivable, net - related party | | | 407 | | | 2,765 |
| Inventory, net | | | 900 | | | 2,821 |
| Income tax receivable | | — | | 697 | ||
| Other receivables | | 4,088 | | 555 | ||
| Prepaid expenses | | 529 | | 8,154 | ||
| Restricted cash | | — | | 408 | ||
| Total current assets | | 43,827 | | 116,158 | ||
| Operating lease right-of-use assets | | | — | | | 4,864 |
| Property and equipment, net | | — | | 3,322 | ||
| Restricted cash, non-current | | — | | 1,500 | ||
| Total assets | | $43,827 | | $125,844 | ||
| Liabilities and stockholders’ equity | | | | |||
| Current liabilities: | | | | |||
| Accounts payable and accrued expenses | | $3,972 | | $25,592 | ||
| Total current liabilities | | 3,972 | | 25,592 | ||
| | | | | | | |
| Liability related to sales of future royalties and milestones, net | | | 44,448 | | | 37,079 |
| Operating lease liabilities, non-current | | | — | | | 6,088 |
| Total liabilities | | 48,420 | | 68,759 | ||
| Commitments and contingencies (Note 19) | | — | | — | ||
| Stockholders’ equity: | | | | |||
| Preferred stock; $0.001 par value; 5,000,000 shares authorized at December 31, 2024 and December 31, 2023, zero shares issued and outstanding at December 31, 2024 and December 31, 2023 | | — | | — | ||
| Common stock; $0.001 par value; 16,666,667 shares and 8,333,333 shares authorized at December 31, 2024 and December 31, 2023, respectively, 4,571,229 shares and 4,540,059 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | 5 | | 5 | ||
| Additional paid-in capital | | 751,014 | | 742,085 | ||
| Accumulated deficit | | (755,612) | | (684,745) | ||
| Accumulated other comprehensive loss | | — | | (260) | ||
| Total stockholders’ equity | | (4,593) | | 57,085 | ||
| Total liabilities and stockholders’ equity | | $43,827 | | $125,844 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.